Lipocine Inc.
LPCN
$1.98
-$0.07-3.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -45.52% | -82.35% | -45.44% | -12.35% | -22.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.52% | -82.35% | -45.44% | -12.35% | -22.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -45.52% | -82.35% | -45.44% | -12.35% | -22.00% |
| SG&A Expenses | -15.44% | -24.74% | -30.57% | -25.27% | -12.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.34% | -0.04% | -19.55% | -32.53% | -32.75% |
| Operating Income | -87.56% | -797.88% | -19.19% | 42.52% | 37.63% |
| Income Before Tax | -112.95% | -107,070.00% | -35.02% | 46.90% | 40.12% |
| Income Tax Expenses | -100.00% | -71.43% | -84.62% | -84.62% | -12.50% |
| Earnings from Continuing Operations | -112.93% | -114,713.10% | -34.99% | 46.90% | 40.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.93% | -114,713.10% | -34.99% | 46.90% | 40.12% |
| EBIT | -87.56% | -797.88% | -19.19% | 42.52% | 37.63% |
| EBITDA | -88.03% | -825.54% | -18.79% | 42.90% | 37.90% |
| EPS Basic | -94.94% | -34,741.18% | -34.18% | 47.32% | 41.01% |
| Normalized Basic EPS | -95.00% | -33,560.61% | -34.23% | 47.32% | 41.02% |
| EPS Diluted | -86.40% | -4,228.36% | -32.29% | 44.93% | 39.01% |
| Normalized Diluted EPS | -91.25% | -8,950.82% | -35.92% | 46.26% | 40.05% |
| Average Basic Shares Outstanding | 8.66% | 2.06% | 0.65% | 0.60% | 1.08% |
| Average Diluted Shares Outstanding | 6.99% | 0.29% | 2.02% | 1.98% | 2.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |